Don’t call it a comeback: Biotech’s CNS resurgence forges Big Pharma connections

Over the course of a harrowing decade, pharmas from GSK and AstraZeneca to Novartis and Pfizer were shuttering their neuroscience drug development programs due to clinical failures, investor risk and frustrating science. In recent years, however, evidence across the industry suggests the brain is back.